Cristina Saura

18.6k total citations · 6 hit papers
201 papers, 4.4k citations indexed

About

Cristina Saura is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Cristina Saura has authored 201 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 163 papers in Oncology, 108 papers in Pulmonary and Respiratory Medicine and 58 papers in Molecular Biology. Recurrent topics in Cristina Saura's work include Advanced Breast Cancer Therapies (84 papers), HER2/EGFR in Cancer Research (83 papers) and Cancer Treatment and Pharmacology (82 papers). Cristina Saura is often cited by papers focused on Advanced Breast Cancer Therapies (84 papers), HER2/EGFR in Cancer Research (83 papers) and Cancer Treatment and Pharmacology (82 papers). Cristina Saura collaborates with scholars based in Spain, United States and France. Cristina Saura's co-authors include Javier Cortés, Mafalda Oliveira, Josep Tabernero, José Baselga, Meritxell Bellet, Sung‐Bae Kim, José Baselga, Santiago Escrivá-de-Romaní, Seock‐Ah Im and Paolo Nucíforo and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Cristina Saura

194 papers receiving 4.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

2019 400 citations Cristina Saura et al. profile →
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

2020 280 citations Cristina Saura, Michelino De Laurentiis et al. profile →
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

2024 144 citations Aditya Bardia, Rebecca Dent et al. profile →
Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).

2024 52 citations Giuseppe Curigliano, Xichun Hu et al. Journal of Clinical Oncology profile →
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study

2024 43 citations Aditya Bardia, Giuseppe Curigliano et al. profile →
Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer

2025 16 citations Komal Jhaveri, Seock‐Ah Im et al. profile →

Peers

Countries citing papers authored by Cristina Saura

Since Specialization

Citations

This map shows the geographic impact of Cristina Saura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cristina Saura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cristina Saura more than expected).

Fields of papers citing papers by Cristina Saura

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cristina Saura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cristina Saura. The network helps show where Cristina Saura may publish in the future.

Co-authorship network of co-authors of Cristina Saura

This figure shows the co-authorship network connecting the top 25 collaborators of Cristina Saura. A scholar is included among the top collaborators of Cristina Saura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cristina Saura. Cristina Saura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Expanding screening through the use of liquid biopsy for early cancer detection 2025 ·Communications Medicine ·Marta Perachino, Carolina Ortiz, Javier Carmona, Cristina Saura, Ana Vivancos	1
2	Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial 2025 ·Clinical Cancer Research ·Mafalda Oliveira, Eva Ciruelos, Guillermo Villacampa, Serafín Morales, Javier Salvador Bofill, Vanesa Quiroga, Joaquín Gavilá Gregori, (unknown), Estela Vega, Fernando Henao, Sònia Servitja, Pablo Tolosa, (unknown), (unknown), Fernando Salvador, Mariana Paes Dias, (unknown), Xavier González, Tomás Pascual, Cristina Saura	0
3	First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses. 2024 ·Journal of Clinical Oncology ·Dejan Juric, Kevin Kalinsky, Nicholas C. Turner, Komal Jhaveri, Peter Schmid, Sherene Loi, Cristina Saura, Seock‐Ah Im, Patrapim Sunpaweravong, Huiping Li, Antonino Musolino, Qingyuan Zhang, Zbigniew Nowecki, Roland Leung, Eirini Thanopoulou, (unknown), Guiyuan Lei, Jacob Devine, Thomas J. Stout, Sibylle Loibl	23
4	Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). breakdown → 2024 ·Journal of Clinical Oncology ·Giuseppe Curigliano, Xichun Hu, Rebecca Dent, Kan Yonemori, Carlos H. Barrios, Joyce O’Shaughnessy, Hans Wildiers, Qingyuan Zhang, Seock‐Ah Im, Cristina Saura, Laura Biganzoli, Joohyuk Sohn, Christelle Lévy, William Jacot, (unknown), Jun Ke, Gargi Patel, Aditya Bardia	52
5	Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd). 2024 ·Journal of Clinical Oncology ·Mark D. Pegram, Carmen Calfa, Christopher S. Chen, Alfonso Cortés, Arielle L. Heeke, Irene Kang, Barbara Pistilli, Paula R. Pohlmann, Hope S. Rugo, Cristina Saura, Cécile Vicier, Cecelia I. Pearson, Milan Mangeshkar, (unknown), Michael N. Alonso, Dawn Colburn, Edith A. Perez, Joshua Z. Drago	1
6	Abstract PO3-16-12: European real-world experience of patients with HER2+ advanced/metastatic breast cancer accessing trastuzumab deruxtecan through a named patient program: first interim analysis of EUROPA T-DXd 2024 ·Cancer Research ·Michelino De Laurentiis, José Á. García-Sáenz, Giampaolo Bianchini, Cristina Saura, Hans Wildiers, Arthur Allignol, (unknown), Markus Lucerna, (unknown)	2
7	GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells 2022 ·Cancers ·Chiara Bellio, (unknown), (unknown), Albert Gris‐Oliver, Françesc Canals, Álex Sánchez‐Pla, Esther Zamora, Joaquı́n Arribas, Cristina Saura, Violeta Serra, Josep Tabernero, Bruce A. Littlefield, Josep Villanueva	12
8	Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response 2022 ·Therapeutic Advances in Medical Oncology ·(unknown), Esther Zamora, Santiago Escrivá-de-Romaní, (unknown), José Jiménez, Cristina Saura, Hillary S. Sloane, (unknown), Johannes Fredebohm, (unknown), Graham Speight, Frederick S. Jones, Santiago Ramón y Cajal, Martín Espinosa-Bravo, Vicente Peg	7
9	Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial 2022 ·European Journal of Cancer ·Guillermo Villacampa, Claudette Falato, Laia Paré, Cristina Hernándo, Míriam Arumí, Cristina Saura, Guadalupe Gómez Melis, Montserrat Muñoz-Mateu, Miguel Gil‐Gil, Yann Izarzugaza, (unknown), (unknown), Álvaro Montaño, Eva Ciruelos, Santiago González-Santiago, Patricia Villagrasa, Joaquín Gavilá, Aleix Prat, Tomás Pascual	4
10	Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer 2021 ·Clinical Cancer Research ·Zhen Shi, Julia Wulfkuhle, Małgorzata Nowicka, Rosa I. Gallagher, Cristina Saura, Paolo Nucíforo, Isabel Calvo, Jay Andersen, José Luís Passos‐Coelho, Miguel Gil‐Gil, Begoña Bermejo, (unknown), Eva Ciruelos, Patricia Villagrasa, Matthew Wongchenko, Emanuel F. Petricoin, Mafalda Oliveira, Steven J. Isakoff	31
11	Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer 2021 ·Clinical Cancer Research ·Cristina Saura, Judit Matito, Mafalda Oliveira, Hans Wildiers, (unknown), Simon Waters, Sara A. Hurvitz, Beverly Moy, Sung‐Bae Kim, William J. Gradishar, Geraldo Silva Queiroz, Eduardo Cronemberger, Gerald Wallweber, Judith D. Bebchuk, Kiana Keyvanjah, Alshad S. Lalani, Richard Bryce, Ana Vivancos, Lisa D. Eli, Suzette Delaloge	15
12	The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1 2020 ·Cancers ·Mercedes Nadal‐Serrano, Beatriz Morancho, Santiago Escrivá-de-Romaní, Cristina Bernadó Morales, Antonio Luque-García, Marta Escorihuela, Martín Espinosa-Bravo, Vicente Peg, Fred A. Dijcks, Wim H.A. Dokter, Javier Cortés, Cristina Saura, Joaquı́n Arribas	39
13	Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer 2020 ·The Breast ·Garazi Serna, S. Simonetti, Roberta Fasani, Francesca Pagliuca, (unknown), (unknown), José Jiménez, Vicente Peg, Cristina Saura, Serenella Eppenberger‐Castori, Santiago Ramón y Cajal, Luigi Terracciano, Paolo Nucíforo	9
14	Breast cancer during pregnancy: matched study of diagnostic approach, tumor characteristics, and prognostic factors 2020 ·Tumori Journal ·Eduardo Reyes, (unknown), Cristina Saura, Martín Espinosa-Bravo, Antonio Gil‐Moreno, Octavi Córdoba	5
15	Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial 2020 ·Breast Cancer Research ·Serena Di Cosimo, Luca Porcu, Dominique Agbor‐Tarh, Saverio Cinieri, Maria Alice Franzoi, Maria Carmen De Santis, Cristina Saura, Jens Huober, Debora Fumagalli, Miguel Izquierdo, Martine Piccart, Maria Grazia Daidone, Evandro de Azambuja	22
16	Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer 2018 ·Clinical Cancer Research ·Maura N. Dickler, Cristina Saura, Donald Richards, Ian E. Krop, Andrés Cervantes, Philippe L. Bédard, Manish R. Patel, Lajos Pusztai, Mafalda Oliveira, (unknown), Na Cui, Timothy R. Wilson, Thomas J. Stout, Michael C. Wei, Jerry Y. Hsu, José Baselga	57
17	HER2-positive breast cancer: Current and new therapeutic strategies 2018 ·The Breast ·Santiago Escrivá-de-Romaní, Míriam Arumí, Meritxell Bellet, Cristina Saura	96
18	Effective Management and Prevention of Neratinib-Induced Diarrhea 2015 ·(unknown), Cristina Saura, (unknown), Richard Bryce, Susan Moran, (unknown), (unknown)	16
19	Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy 2014 ·Clinical Cancer Research ·Cristina Saura, Johanna C. Bendell, Guy Jérusalem, (unknown), Qinhua Ru, Stefan Buck, David Mills, (unknown), Ana Bosch, Ander Urruticoechea, J. Thaddeus Beck, Emmanuelle di Tomaso, David Sternberg, Cristian Massacesi, Samit Hirawat, Luc Dirix, José Baselga	110
20	Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer 2013 ·Clinical Cancer Research ·Christine E. Horak, Lajos Pusztai, Guan Xing, Ovidiu C. Trifan, Cristina Saura, Ling‐Ming Tseng, Stephen Chan, (unknown), David Liu	83

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact